The alliance, agreed for three years, will allow the main public hospital in the country to have the drug Ravulizumab , a latest generation therapy used in rare diseases related to alterations of the complement system.
The alliance, agreed for three years, will allow the main public hospital in the country to have the drug Ravulizumab , a latest generation therapy used in rare diseases related to alterations of the complement system.